title: European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.
abstract: BACKGROUND
  Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatment guidance focused on the musculoskeletal manifestations of PsA would be advantageous. The authors present European League Against Rheumatism (EULAR) recommendations for the treatment of PsA with systemic or local (non-topical) symptomatic and disease-modifying antirheumatic drugs (DMARD).
  
  
  METHODS
  The recommendations are based on evidence from systematic literature reviews performed for non-steroidal anti-inflammatory drugs (NSAID), glucocorticoids, synthetic DMARD and biological DMARD. This evidence was discussed, summarised and recommendations were formulated by a task force comprising 35 representatives, and providing levels of evidence, strength of recommendations and levels of agreement.
  
  
  RESULTS
  Ten recommendations were developed for treatment from NSAID through synthetic DMARD to biological agents, accounting for articular and extra-articular manifestations of PsA. Five overarching principles and a research agenda were defined.
  
  
  CONCLUSIONS
  These recommendations are intended to provide rheumatologists, patients and other stakeholders with a consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes, based on combining evidence and expert opinion. The research agenda informs directions within EULAR and other communities interested in PsA.
authors.affiliation: Paris Descartes University, Paris, France. laure.gossec@cch.aphp.fr
authors.forename: L
authors.initials: L
authors.lastname: Gossec
authors.forename: J S
authors.initials: JS
authors.lastname: Smolen
authors.forename: C
authors.initials: C
authors.lastname: Gaujoux-Viala
authors.forename: Z
authors.initials: Z
authors.lastname: Ash
authors.forename: H
authors.initials: H
authors.lastname: Marzo-Ortega
authors.forename: D
authors.initials: D
authors.lastname: van der Heijde
authors.forename: O
authors.initials: O
authors.lastname: FitzGerald
authors.forename: D
authors.initials: D
authors.lastname: Aletaha
authors.forename: P
authors.initials: P
authors.lastname: Balint
authors.forename: D
authors.initials: D
authors.lastname: Boumpas
authors.forename: J
authors.initials: J
authors.lastname: Braun
authors.forename: F C
authors.initials: FC
authors.lastname: Breedveld
authors.forename: G
authors.initials: G
authors.lastname: Burmester
authors.forename: J D
authors.initials: JD
authors.lastname: Cañete
authors.forename: M
authors.initials: M
authors.lastname: de Wit
authors.forename: H
authors.initials: H
authors.lastname: Dagfinrud
authors.forename: K
authors.initials: K
authors.lastname: de Vlam
authors.forename: M
authors.initials: M
authors.lastname: Dougados
authors.forename: P
authors.initials: P
authors.lastname: Helliwell
authors.forename: A
authors.initials: A
authors.lastname: Kavanaugh
authors.forename: T K
authors.initials: TK
authors.lastname: Kvien
authors.forename: R
authors.initials: R
authors.lastname: Landewé
authors.forename: T
authors.initials: T
authors.lastname: Luger
authors.forename: M
authors.initials: M
authors.lastname: Maccarone
authors.forename: D
authors.initials: D
authors.lastname: McGonagle
authors.forename: N
authors.initials: N
authors.lastname: McHugh
authors.forename: I B
authors.initials: IB
authors.lastname: McInnes
authors.forename: C
authors.initials: C
authors.lastname: Ritchlin
authors.forename: J
authors.initials: J
authors.lastname: Sieper
authors.forename: P P
authors.initials: PP
authors.lastname: Tak
authors.forename: G
authors.initials: G
authors.lastname: Valesini
authors.forename: J
authors.initials: J
authors.lastname: Vencovsky
authors.forename: K L
authors.initials: KL
authors.lastname: Winthrop
authors.forename: A
authors.initials: A
authors.lastname: Zink
authors.forename: P
authors.initials: P
authors.lastname: Emery
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D015897:Comorbidity; D005060:Europe; D019317:Evidence-Based Medicine / Q000379:methods; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007391:International Cooperation; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D018501:Antirheumatic Agents; D005938:Glucocorticoids; D014409:Tumor Necrosis Factor-alpha